



AcryMed Hires Medical Industry Veteran to Manage Antimicrobial Business

David Rardin appointed VP of marketing & business development.

PORTLAND, Oregon (PRWeb) January 18, 2007 -- AcryMed, a medical technology company specializing in wound care and infection control, today announced the appointment of David Rardin as the company's vice president of marketing and business development. Rardin, a twenty-one year industry veteran, will focus on the company's SilvaGard® business, which has received increased interest as a breakthrough antimicrobial treatment technology for medical devices.

SilvaGard is a highly effective and safe, broad spectrum, antimicrobial treatment that incorporates nanoparticles of silver to combat bacteria, including methicillin-resistant Staph aureus (MRSA). In December 2005, SilvaGard antimicrobial treatment received its first market clearance for incorporation with indwelling catheters. AcryMed has several other development projects underway that address SilvaGard's incorporation with additional percutaneous and implantable devices and expects to announce new licensing agreements in the coming months. In his role, Rardin will manage these new agreements and help AcryMed generate and manage future business opportunities.

"With the growing concern for reducing hospital acquired infections (HAI), SilvaGard's attributes as a uniquely safe and versatile antimicrobial treatment technology has drawn quite a bit of attention within the medical device community," said Jack D. McMaken, president and CEO of AcryMed Inc. "Rardin's skills and expertise in this market will be instrumental in helping AcryMed manage this enormous industry interest as well as helping to steer our growth in the future."

Rardin has over twenty years of diversified experience within the medical products industry including positions responsible for marketing, sales, management and training. Prior to joining AcryMed, Rardin was vice president of global marketing for Conor Medsystems, Inc. (CONR), which recently announced its acquisition by Johnson & Johnson (JNJ) and led efforts to successfully launch and manage the company's CoStar® drug-eluting stent (DES). Prior to that, Rardin held management positions with Medtronic (MDT), Guidant Vascular Intervention (now part of Abbott (ABT)), Precision Vascular Systems acquired by Boston Scientific (BSX) and C.R. Bard (BCR).

"I believe SilvaGard technology is a significant breakthrough in the war against hospital acquired infections and has tangible benefits for patients, healthcare providers and the medical industry," said Rardin. "I look forward to collaborating with our research teams and medical device partners to leverage the broad applicability of SilvaGard antimicrobial technology in the battle against this devastating and costly medical concern."

About AcryMed

AcryMed is a pioneering innovator in the field of silver antimicrobial infection control. The company's SilvaSorb® products for advance wound care and SilvaGard nanoparticle surface treatment for medical devices are among the breakthrough technologies that have distinguished AcryMed as industry leaders. AcryMed, maintains on-site GMP manufacturing and GLP lab facilities at its Portland, Oregon-based headquarters. The



company is ISO certified and operates under ISO 13485 and EN 93/42/EEC. For more information on AcryMed, SilvaSorb, SilvaGard or other wound care and infection control technologies developed by AcryMed, visit their web site at www.acrymed.com or call 503-624-9830.

###



Contact Information

BRAD BRENNER

AcryMed Inc.

<http://www.acrymed.com>

503-736-0610

Online Web 2.0 Version

You can read the online version of this press release [here](#).